Intellectual Property and AI-Generated Innovations
Expert-defined terms from the Professional Certificate in AI Ethics and Regulatory Compliance in Pharma course at Stanmore School of Business. Free to read, free to share, paired with a professional course.
Algorithmic Patentability #
Algorithmic Patentability
A legal assessment of whether a computer‑implemented method meets the statutory… #
In pharma, it may cover AI‑driven drug‑discovery workflows. Example: a novel neural‑network model that predicts protein‑ligand binding is examined for technical contribution beyond abstract ideas. Challenges include jurisdictional variance and the “mental processes” exclusion.
Artificial Intelligence (AI) #
Artificial Intelligence (AI)
The simulation of human intelligence processes by machines, especially algorithm… #
In pharmaceutical research, AI accelerates target identification, synthesis planning, and clinical trial optimization. Practical application: using generative models to propose new molecular scaffolds. Ethical concerns involve bias, transparency, and data privacy.
AI‑Generated Data #
AI‑Generated Data
Data created by algorithms rather than measured experimentally #
Synthetic patient records can be used to train predictive models while protecting privacy. Example: a GAN produces realistic electrocardiogram waveforms for algorithm validation. Challenges include ensuring statistical fidelity and avoiding inadvertent disclosure of original datasets.
AI‑Generated Invention #
AI‑Generated Invention
An invention that originates from the output of an autonomous AI system, such as… #
Patent offices debate whether the AI can be listed as an inventor. Practical scenario: an AI suggests a previously unknown polymorph with improved solubility. Issues revolve around legal personhood and attribution.
AI‑Generated Knowledge Base #
AI‑Generated Knowledge Base
A structured repository of information compiled by AI from literature, patents,… #
Used to support drug‑repurposing decisions. Example: an AI curates relationships between disease pathways and existing drugs. Challenges include provenance tracking and updating mechanisms.
AI‑Generated Patent Claims #
AI‑Generated Patent Claims
Claims that are automatically written or suggested by AI based on prior art anal… #
They can improve breadth and clarity. Example: a tool proposes a claim hierarchy for a CRISPR‑based therapy. Risks involve over‑reliance on AI leading to ambiguous language or inadvertent infringement.
AI‑Generated Research Output #
AI‑Generated Research Output
Manuscripts, figures, or experimental plans produced by AI #
In pharma, AI may draft sections of a clinical trial protocol. Example: an AI writes a methods section describing a Bayesian adaptive design. Ethical questions pertain to accountability and proper attribution.
AI‑Informed Consent #
AI‑Informed Consent
A process where AI assists in explaining complex trial procedures to participant… #
It can personalize risk communication. Example: a chatbot answers participant questions about a gene‑therapy trial. Challenges include ensuring comprehension and avoiding undue influence.
AI‑Model Transparency #
AI‑Model Transparency
The degree to which the inner workings of an AI system can be understood by huma… #
Critical for regulatory acceptance of AI‑driven diagnostics. Example: Shapley values reveal which molecular descriptors drive a toxicity prediction. Obstacles include trade‑offs between performance and interpretability.
AI‑Regulated Product #
AI‑Regulated Product
A product whose functionality depends on AI and is subject to regulatory oversig… #
In pharma, AI‑based dosing calculators fall under this category. Example: an FDA‑cleared algorithm that adjusts chemotherapy dosage based on real‑time blood counts. Compliance requires post‑market monitoring and robust validation.
Algorithmic Bias #
Algorithmic Bias
Systematic error introduced by training data or model design that leads to unequ… #
In drug discovery, bias may cause under‑representation of rare disease targets. Mitigation strategies include balanced datasets and bias‑audit tools.
Algorithmic Ownership #
Algorithmic Ownership
Legal rights over the source code, model parameters, and training data of an AI… #
Companies may own the algorithm, while collaborators retain rights to underlying data. Example: a pharma‑AI joint venture assigns algorithmic ownership to the biotech partner. Issues arise when open‑source components are incorporated.
Authorship Attribution #
Authorship Attribution
The process of assigning credit to individuals who created or contributed to a w… #
In AI‑generated manuscripts, human authors must disclose AI assistance. Example: a paper lists “AI‑assisted writing” in the methods. Failure to attribute can breach journal policies and ethical standards.
Biological Data Patentability #
Biological Data Patentability
Evaluation of whether naturally occurring or AI‑designed biological sequences qu… #
Post‑Myriad decisions limit patents on isolated DNA, but synthetic sequences remain eligible. Example: an AI‑designed antibody fragment is claimed as a composition of matter. Legal uncertainty persists around “product of nature” doctrines.
Biomarker Discovery AI #
Biomarker Discovery AI
Use of machine learning to uncover molecular signatures linked to disease progre… #
Example: an AI identifies a miRNA panel predicting response to a checkpoint inhibitor. Commercialization involves co‑development of a diagnostic assay and navigating regulatory pathways.
Clinical Decision Support (CDS) AI #
Clinical Decision Support (CDS) AI
Software that provides clinicians with evidence‑based suggestions, often powered… #
Example: an AI recommends dosage adjustments for warfarin based on patient genetics. Regulatory classification may be SaMD; compliance demands rigorous validation and risk management.
Computational Patent Search #
Computational Patent Search
Automated tools that scan patent databases to locate relevant prior art #
AI can improve recall and relevance ranking. Example: a pharma company uses a semantic search engine to assess freedom‑to‑operate for a CRISPR therapeutic. Limitations include false positives and language‑specific coverage.
Confidentiality in AI Training Data #
Confidentiality in AI Training Data
Obligations to protect proprietary or patient data used to train models #
De‑identification and secure environments are required. Example: a contract stipulates that raw clinical trial data cannot be exported from the cloud. Breaches may trigger legal liability and loss of competitive advantage.
Contractual AI Licensing #
Contractual AI Licensing
Agreements governing the use, modification, and distribution of AI tools #
In pharma, licenses may include clauses on data ownership, indemnity, and compliance with GMP. Example: a biotech firm licenses an AI platform for molecule generation with a per‑molecule royalty. Negotiations must address downstream IP generated by the AI.
Creative Commons for AI‑Generated Content #
Creative Commons for AI‑Generated Content
Data Governance #
Data Governance
Policies and procedures that ensure data integrity, security, and compliance thr… #
In AI development, governance covers raw clinical data, model training sets, and generated outputs. Example: a pharma company implements a data‑access matrix aligned with GDPR. Weak governance can undermine model reliability and regulatory acceptance.
Data Provenance #
Data Provenance
Documentation of the origin, transformations, and ownership of data used in AI p… #
Essential for auditability and reproducibility. Example: a metadata tag records that a training set originated from a Phase II trial and was de‑identified per HIPAA. Lack of provenance may lead to disputes over IP ownership.
Data Privacy Regulations #
Data Privacy Regulations
Legal statutes that protect personal information #
AI models that process patient data must comply with consent, minimization, and security requirements. Example: an AI platform encrypts raw genomic sequences before training. Non‑compliance can result in fines and loss of public trust.
Data Rights Management #
Data Rights Management
Mechanisms that define who can use, modify, or commercialize datasets #
In collaborative AI projects, rights may be split between data providers and model developers. Example: a consortium adopts a data‑use agreement that grants non‑exclusive, royalty‑free rights for internal research only. Misalignment can stall project timelines.
Deep Learning Patent Landscape #
Deep Learning Patent Landscape
Analysis of existing patents covering deep‑learning architectures, training meth… #
Helps identify gaps and avoid infringement. Example: a company discovers that a particular convolutional architecture for image‑based pathology is patented by a competitor. Landscape studies must be regularly updated due to rapid filing rates.
Digital Therapeutic IP #
Digital Therapeutic IP
Intellectual property protection for software‑based treatments, such as AI‑drive… #
Example: a patented algorithm that personalizes behavioral interventions for smoking cessation. Challenges include aligning patent claims with FDA’s SaMD framework and ensuring that IP does not hinder patient access.
Disclosure Obligations for AI‑Generated Inventions #
Disclosure Obligations for AI‑Generated Inventions
Legal duties to disclose AI‑originated inventions to patent offices and internal… #
Example: a researcher submits a disclosure form noting that the core claim was derived from a generative model. Failure to disclose may invalidate later patents and breach institutional policies.
Ethical AI Frameworks #
Ethical AI Frameworks
Structured sets of principles guiding the development and deployment of AI #
In pharma, frameworks address safety, fairness, and transparency. Example: a company adopts the EU’s “Trustworthy AI” guidelines for its drug‑discovery platform. Implementation requires cross‑functional governance and continuous monitoring.
Fair Use in AI‑Generated Works #
Fair Use in AI‑Generated Works
Legal doctrine allowing limited use of copyrighted material without permission f… #
AI training on copyrighted literature may be defended under fair use if the use is transformative. Example: an AI model trained on publicly available abstracts to predict drug efficacy. Courts have not yet settled on AI‑specific fair‑use boundaries, creating uncertainty.
Generative Model Patentability #
Generative Model Patentability
Evaluation of whether a model that creates new chemical structures can be patent… #
Example: a patent on a GAN that outputs novel heterocyclic cores, with claims covering the generated molecules themselves. Issues include the “abstract idea” exclusion and the need for concrete embodiment.
Genomic Data IP #
Genomic Data IP
Protection of genetic information, whether through patents on isolated sequences… #
AI that predicts functional variants from genome data must respect existing rights. Example: a company files a patent on an AI‑derived allele associated with drug metabolism. Over‑broad claims risk invalidation under recent jurisprudence.
Global AI Regulatory Landscape #
Global AI Regulatory Landscape
Overview of how different jurisdictions treat AI in pharma, including classifica… #
Example: the US FDA’s “Good Machine Learning Practice” guidance versus the EU’s “AI Act” proposals. Companies must navigate divergent timelines and compliance burdens.
Human‑In‑the‑Loop (HITL) Systems #
Human‑In‑the‑Loop (HITL) Systems
AI systems that require human validation before final action #
In drug safety monitoring, AI flags signals, but pharmacovigilists confirm them. Example: an HITL pipeline reduces false‑positive adverse‑event alerts by 30%. Designing effective HITL balances efficiency with accountability.
Invention Disclosure for AI‑Assisted Discoveries #
Invention Disclosure for AI‑Assisted Discoveries
Formal process of reporting new inventions that involve AI contributions #
Example: a lab submits an internal disclosure noting that a molecular scaffold was suggested by a reinforcement‑learning agent. Proper disclosure enables timely patent filing and protects against prior‑art challenges.
Intellectual Property (IP) Strategy for AI #
Intellectual Property (IP) Strategy for AI
Inventorship Determination #
Inventorship Determination
Legal analysis of who qualifies as an inventor under patent statutes #
AI contributions raise questions about whether a human who directed the AI or the AI itself should be named. Example: courts have held that only natural persons can be inventors, so the human who conceptualized the AI‑driven invention must be listed. Ambiguities may cause invalidation if omitted.
Joint Development Agreement (JDA) for AI Projects #
Joint Development Agreement (JDA) for AI Projects
Contract governing co‑creation of AI tools, specifying IP ownership, data rights… #
Example: two biotech firms co‑develop an AI platform for peptide design, agreeing that each retains rights to molecules they independently commercialize. Poorly drafted JDAs can lead to disputes over downstream patents.
Knowledge Transfer Agreements #
Knowledge Transfer Agreements
Legal instruments that facilitate the movement of AI expertise, models, and data… #
Example: a university licenses its AI‑based pharmacokinetic predictor to a pharma partner, including training for the partner’s scientists. Effective agreements balance protection of academic IP with commercial exploitation.
Machine‑Learning Model Validation #
Machine‑Learning Model Validation
Systematic assessment of model performance, robustness, and generalizability #
In pharma, validation must meet regulatory expectations for safety‑critical applications. Example: a cross‑validation study demonstrates that an AI model predicts hepatotoxicity with >90% AUROC across three external datasets. Validation gaps can delay approvals.
Model Drift Monitoring #
Model Drift Monitoring
Continuous observation of AI behavior to detect changes caused by new data or sh… #
Example: an AI dose‑adjustment tool is re‑trained annually to incorporate emerging resistance patterns. Failure to monitor drift may lead to unsafe recommendations and regulatory penalties.
Neural‑Network Patent Claims #
Neural‑Network Patent Claims
Drafting of patent claims that cover specific neural‑network architectures, trai… #
Example: a claim recites a “convolutional neural network comprising layers A, B, and C configured to predict protein folding.” Patent examiners often scrutinize such claims for abstractness.
Open‑Source AI Licenses #
Open‑Source AI Licenses
Legal terms that permit free use, modification, and distribution of software, of… #
In pharma, open‑source AI can accelerate innovation but may complicate IP protection. Example: a company adopts Apache 2.0 for its molecule‑generation toolkit, requiring downstream users to retain the license notice. Compatibility with proprietary components must be assessed.
Patent Infringement Risk Assessment #
Patent Infringement Risk Assessment
Evaluation of whether a proposed AI‑driven product might violate existing patent… #
Involves mapping AI‑generated molecules against claim scopes. Example: a risk assessment flags a potential infringement on a patent covering a class of kinase inhibitors generated by an AI. Mitigation may involve design‑around or licensing.
Patent Portfolio Management for AI‑Enabled Drugs #
Patent Portfolio Management for AI‑Enabled Drugs
Patent Term Extensions (PTE) for AI‑Derived Medicines #
Patent Term Extensions (PTE) for AI‑Derived Medicines
Extensions granted to compensate for time lost during regulatory review, often a… #
Example: a biotech seeks PTE for an AI‑designed antibody that required extensive clinical testing. Aligning PTE with AI‑specific IP can enhance commercial viability.
Patent Trolls and AI #
Patent Trolls and AI
Entities that acquire patents primarily to enforce them against alleged infringe… #
AI‑related patents are attractive due to high valuation. Example: a non‑practicing entity sues a pharma firm for alleged infringement of an AI‑based predictive model. Defensive strategies include patent pools and cross‑licensing.
Predictive Modeling IP #
Predictive Modeling IP
Intellectual property rights covering models that forecast outcomes such as effi… #
Example: a patented predictive algorithm that estimates clinical trial success probability based on preclinical data. Protecting such models requires balancing patent breadth with confidentiality of training data.
Privacy‑Preserving Machine Learning #
Privacy‑Preserving Machine Learning
Techniques that enable AI training on distributed data without exposing raw reco… #
In pharma, federated learning allows multiple hospitals to collaboratively improve a safety‑prediction model. Example: a federated network trains a model on patient EHRs while keeping data on local servers. Compliance with privacy laws is a primary driver.
Proprietary Data Sets #
Proprietary Data Sets
Data collections that provide a competitive edge and are protected from disclosu… #
AI models trained on proprietary high‑throughput screening results can generate unique insights. Example: a pharma company classifies its kinase assay library as a trade secret, limiting external sharing. Loss of confidentiality can erode IP advantage.
Regulatory Compliance for AI‑Generated Labels #
Regulatory Compliance for AI‑Generated Labels
Ensuring that AI‑derived product information meets agency standards. Example #
an AI system suggests new contraindications based on post‑market data, which must be reviewed and approved before label update. Documentation of AI methodology is often required for audit trails.
Regulatory Submission of AI Models #
Regulatory Submission of AI Models
Inclusion of AI model details in dossiers submitted to regulators. Example #
an FDA pre‑market submission includes model architecture, training data description, performance metrics, and risk mitigation plan. Inadequate disclosure can result in rejection or post‑approval enforcement actions.
Research Ethics Committee (REC) Review of AI Studies #
Research Ethics Committee (REC) Review of AI Studies
Oversight of studies involving AI that may affect participants. Example #
a clinical trial using AI to allocate patients to treatment arms must be approved by an REC, ensuring transparency and risk minimization. Ethical review often focuses on algorithmic bias and informed consent.
Responsible AI Governance #
Responsible AI Governance
Organizational structures and policies that guide ethical AI development #
Example: a pharma firm establishes an AI Ethics Committee that reviews all AI projects for fairness, safety, and compliance. Governance must be integrated with existing R&D and compliance functions.
Risk‑Based Approach to AI Validation #
Risk‑Based Approach to AI Validation
Prioritizing validation activities based on the potential impact of AI errors #
Example: a high‑risk AI diagnostic tool undergoes extensive verification, while a low‑risk data‑cleaning script receives lighter testing. This approach aligns with ISO 14971 and FDA guidance.
Scientific Collaboration Agreements for AI #
Scientific Collaboration Agreements for AI
Search Engine Optimization (SEO) for AI‑Generated Content #
Search Engine Optimization (SEO) for AI‑Generated Content
Techniques to improve discoverability of AI‑produced scientific articles #
Example: using appropriate metadata tags for AI‑generated preprints to ensure indexing by PubMed. Over‑optimizing can raise ethical concerns about misrepresentation of authorship.
Security of AI Models #
Security of AI Models
Protection against unauthorized access, manipulation, or reverse engineering of… #
Example: an attacker crafts adversarial inputs that cause a toxicity prediction model to misclassify hazardous compounds as safe. Countermeasures include input sanitization and encryption of model weights.
Software Patent Eligibility #
Software Patent Eligibility
Analysis of whether a computer‑implemented invention qualifies for patent protec… #
In pharma, claims often tie software to a specific therapeutic application to meet the “technical effect” requirement. Example: a claim recites a method for “optimizing dosage based on real‑time biomarker data” implemented by a computer. Courts scrutinize whether the claim is merely an abstract algorithm.
Strategic Patent Filing for AI‑Generated Molecules #
Strategic Patent Filing for AI‑Generated Molecules
Timing and scope decisions for protecting AI‑designed compounds. Example #
filing a provisional patent on a promising scaffold generated by AI before synthesis, followed by a full utility application after experimental validation. Early filing secures priority but may limit claim breadth if the AI later discovers superior analogs.
Technology Transfer of AI Platforms #
Technology Transfer of AI Platforms
Moving AI innovations from research labs to commercial entities. Example #
a university creates a spin‑out to commercialize its AI‑based virtual screening engine, negotiating exclusive licensing with a pharma partner. Successful transfer requires clear IP ownership, regulatory pathways, and market analysis.
Trade Secret Protection for Training Data #
Trade Secret Protection for Training Data
Legal mechanisms to keep data used for AI model training undisclosed. Example #
a pharma firm requires employees to sign NDAs that specifically cover the proprietary high‑content screening dataset. Trade‑secret loss can be catastrophic, especially when data is a core competitive asset.
Trademark Issues for AI‑Named Products #
Trademark Issues for AI‑Named Products
Protecting names generated by AI for drugs, devices, or digital therapeutics #
Example: an AI suggests the brand “NeuroVita” for a CNS therapeutic; the company conducts a trademark search and files for registration. Over‑reliance on AI may overlook existing marks, leading to infringement risk.
Validation Dataset Bias #
Validation Dataset Bias
Systematic errors introduced when the dataset used to evaluate an AI model is no… #
Example: an AI toxicity predictor is validated only on compounds from a single chemical library, inflating performance metrics. Mitigation includes diverse external datasets and stratified sampling.
Version Control for AI Models #
Version Control for AI Models
Tracking of model iterations, parameters, and associated documentation. Example #
a pharma AI team uses a model registry to record each release of a pharmacokinetic predictor, linking it to the data version and performance report. Proper versioning supports reproducibility and regulatory auditability.
WIPO AI and IP Guidelines #
WIPO AI and IP Guidelines
World Intellectual Property Organization publications that outline best practice… #
Example: the WIPO “AI and IP” report discusses how to draft claims that survive subject‑matter eligibility challenges. Aligning corporate IP strategy with WIPO guidance can facilitate global filing.
Work‑Product Doctrine for AI Research #
Work‑Product Doctrine for AI Research
Legal principle protecting materials prepared in anticipation of litigation #
In pharma, AI research notes may be shielded if they are part of a defensive strategy. Example: a company invokes the work‑product doctrine to withhold AI‑generated risk analyses from discovery requests. Applicability varies by jurisdiction.